Get the Stockscreener App
1.21
7.92%
+0.0888
After Hours:
1.21
Akari Therapeutics Plc ADR stock is currently priced at $1.21, with a 24-hour trading volume of 8,776.
It has seen a +7.92% increased in the last 24 hours and a -39.50% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.15 pivot point. If it approaches the $1.21 resistance level, significant changes may occur.
Akari Therapeutics Plc ADR Stock (AKTX) Financials Data
There is no financial data for Akari Therapeutics Plc ADR (AKTX). Check out other stocks for more information.
Akari Therapeutics Plc ADR Stock (AKTX) Latest News
Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights
GlobeNewswire Inc.
Akari Therapeutics to Present at Biotech Showcase 2024
GlobeNewswire Inc.
Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors
GlobeNewswire Inc.
About Akari Therapeutics Plc ADR
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
COMPANY PROFILE
NameAkari Therapeutics Plc ADR
SectorHealthcare (1194)
IndustryBiotechnology (685)
Webakaritx.com
Phone44 20 8004 0270
Employee9
Twitter
@AkariTX
SEC filings
Latest SEC Filings
Next earning date2024-04-29
Address75/76 Wimpole Street, London, United Kingdom (W1G 9RT)
0.08%
0.44%
Cap:
|
Volume (24h):